[1] Cho N H,Shaw J E,Karuranga S,et al.IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045[J]. Diabetes Research & Clinical Practice, 2018:271.
[2] 中国老年2型糖尿病防治临床指南(2022年版)[J]. 中国糖尿病杂志,2022,30(1):2-51.
[3] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志(中英文), 2018, 2(4):30.
[4] 杨宏斌,黄巧平.老年心功能衰竭患者血清NT-proBNP和hs-TnT水平检测与NYHA分级的相关性分析[J]. 现代检验医学杂志, 2019, 34(2):5.
[5] 曾又晓,黄雪娥,吴淑燕.达格列净片治疗冠心病合并2型糖尿病患者的效果研究[J].心血管病防治知识:学术版,2021,11(14):3.
[6] 母义明, 纪立农, 李春霖,等. 二甲双胍临床应用专家共识(2018年版)[J]. 中国糖尿病杂志, 2019, 27(3):13.
[7] 刘翩,周小翠,汪涛.达格列净片治疗2型糖尿病合并心力衰竭患者的临床研究[J]. 中国临床药理学杂志, 2021, 37(3):4.
[8] Garcia-Ropero A, Badimon J J, Santos-Gallego C G. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments[J]. Expert Opinion on Drug Metabolism & Toxicology, 2018.
[9] Hallow K M, Helmlinger G, Greasley P J, et al.Why do SGLT2 inhibitors reduce heart failure hospitalization A differential volume regulation hypothesis[J]. Diabetes Obesity & Metabolism, 2018.
[10] Packer M .Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion[J]. Cardiovascular Diabetology, 2019, 18.
[11] Zhang N, Feng B, Ma X, et al.Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction[J]. Cardiovascular Diabetology, 2019, 18. |
